Josh Ofman

Josh Ofman has led the clinical and commercial development of CancerSEEK-based multi-cancer detection at Thrive Earlier Detection (now Exact Sciences), advancing the multi-analyte blood test combining ctDNA and protein biomarkers through clinical validation and toward regulatory approval. His work has established the clinical diagnostic pathway for MCED-positive patients, ensuring that detected cancer signals are efficiently resolved through appropriate confirmatory imaging and tissue diagnosis. He has developed health economic models demonstrating the cost-effectiveness of adding MCED to existing cancer screening programs. His regulatory strategy work has shaped FDA's evolving framework for MCED test approval.